Alexion will construct a biologics facility in Ireland that is its first outside the US.
Alexion Pharmaceuticals plans to significantly expand its operations in Ireland by constructing the company’s first biologics manufacturing facility outside the United States, the company announced on May 11, 2015. This €450 million (approximately US$500 million), four-year project, which will be constructed at Alexion’s College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, which will bring Alexion’s total workforce in Ireland to almost 500 employees.
Since first entering Ireland in 2013, Alexion has invested €130 million (US$145 million) in two facilities-a vial fill-finish facility in Athlone and a global supply-chain facility at College Park. Phase one of the College Park facility, which will comprise the Global Supply Chain headquarters, laboratories, packaging, and warehousing operations, is expected to be operational by year-end.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.